Nesrin Gareayaghi

Nesrin Gareayaghi

Auto-generated profile, based on publicly available information

Nesrin Gareayaghi

Sağlık Bilimleri Üniversitesi, Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Kan Merkezi, İstanbul

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
NGNesrin Gareayaghi
Nesrin Gareayaghi
BKBekir Kocazeybek
Bekir Kocazeybek
Reports have indicated an increasing prevalence of clarithromycin resistance in children relative to adults. Thus, it is important to investigate primary clarithromycin resistance before therapy to avoid treatment failure. A2142G, A2143G, and A2142C point mutations in the peptidyltransferase region of the 23S ribosomal RNA (rRNA) of Helicobacter pylori (H. pylori) strains isolated from children with gastrointestinal symptoms and asymptomatic children were evaluated via real-time polymerase chain reaction (RT-PCR) using fecal DNA samples. The presence of H. pylori was determined using a fecal H. pylori antigen enzyme-linked immunosorbent assay (ELISA) kit from the stools of children (n = 543). A2143G, A2142C, and A2142G point mutations were detected via RT-PCR and confirmed by sequencing the 23S rDNA. Fecal H. pylori antigen testing was positive in 101 symptomatic (49) and asymptomatic (52) children. A significant difference was found between the 0–5- and 5–18-year-old groups in terms of the A2143G and A2142G point mutations (p = 0.001). The A2142C mutation was not detected. There was a significant difference in the A2143G mutation between the symptomatic and asymptomatic 5–18-year-old children (p = 0.019). Macrolides are frequently used to treat upper respiratory tract infections in children due to their selective pressure effect. We suggest that H. pylori strains carrying mutations in the 23S RNA subunit conferring clarithromycin resistance may lead to an intense inflammatory response in the gastric epithelial cells, allowing them to proliferate more rapidly and causing possible diarrhea, halitosis, or abdominal pain in children.

5 April 2022 in Balkan Medical Journal
Verified
Journal Article
Open access
HDHarika Öykü Dinç
Harika Öykü Dinç
Mehmet DemirciMehmet Demirci
Mehmet Demirci
YOYusuf Emre Ozdemir
Yusuf Emre Ozdemir
Serhat SirekbasanSerhat Sirekbasan
Serhat Sirekbasan
AAAyse Nur Aktaş
Ayse Nur Aktaş
BKBekir Kocazeybek
Bekir Kocazeybek
Background: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections is vital to understanding the role of antibodies in preventing infection. Aims: To determine the quantitative IgG responses specific to the Spike-S1 (S1) receptor-binding domain (S1/RBD) region of the virus in serum samples taken between 4 weeks and 7 months after polymerase chain reaction (PCR) positivity in patients who are diagnosed with coronavirus disease-2019 (COVID-19). Study Design: A longitudinal study. Methods: This study included 113 patients with a clinical and molecular diagnosis of COVID-19. The first and second serum samples were taken 1 and 7 months, respectively, after the PCR positivity. S1/ RBD-specific IgG antibody response was assayed using anti-SARS-CoV-2 QuantiVac ELISA (IgG) kit (Euroimmun, Lubeck, Germany). The neutralizing antibodies were investigated in 57 patients whose IgG test results were above the cut-off value. Results: In 57 patients with SARS-CoV-2 IgG, the anti-SARS-CoV-2 IgG quantitative antibody levels significantly decreased after 7 months (Z = -2.197, p = 0.028). A correlation was detected between the anti-SARS-CoV-2 IgG and nAb percent inhibition (IH%) levels detected in 1 month (rs = 0.496, p < 0.001), but without significant correlation in serum samples taken on 7 months. The nAb IH% levels of the first and second were compared for COVID-19 severity and revealed no statistical difference (p = 0.256). In the second serum sample, the nAb IH%s of patients with moderate COVID-19 showed a statistically significant difference from patients with mild COVID-19 (p = 0.018), but without significant differences between severe and moderate or mild COVID-19. Conclusion: SARS-CoV-2 quantitative IgG antibody titers are significantly reduced at long-term follow-up (> 6 months). Due to the limited information on seroconversion, comprehensive studies should be conducted for long-term follow-up of the immune response against SARS-CoV-2.

19 April 2021 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
HDHarika Öykü Dinç
Harika Öykü Dinç
YOYusuf Emre Ozdemir
Yusuf Emre Ozdemir
SASena Alkan
Sena Alkan
ZDZeynep Güngördü Dalar
Zeynep Güngördü Dalar
NGNesrin Gareayaghi
Nesrin Gareayaghi
BKBekir Kocazeybek
Bekir Kocazeybek
Following the emergence of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) and using only PCR for diagnosis, antibody tests have been rapidly developed by various commercial companies. There are differences between the sensitivity and specificity of these tests due to the usage of different viral target proteins and antibody subclasses. In order to evaluate the diagnostic use of these tests, we aimed to examine the diagnostic performance, especially sensitivity and specificity, of SARS-CoV-2 IgM, IgA and IgG tests of various companies (Abbott, Roche, Euroimmun, Dia.Pro, Anshlabs, Vircell, UnScience and RedCell), which have different principles (ECLIA/CLIA, EIA, LFA). Current (n= 180) and past (n= 180) COVID-19 patients with clinical and molecular diagnosis of COVID-19 admitted to Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine Hospital, Pandemic Polyclinic with suspected COVID-19 infection, were included in our study. The patients admitted within the first 3 weeks after the onset of symptoms were included in the current patient group, and those admitted at the third and after the third week were included in the past patient group. Serum samples (n= 180) obtained from Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Blood Center between April and June 2018 before the COVID-19 pandemic were included in the study as a control group. All the tests included in our study were studied with the recommendations of the manufacturer companies. Between the IgG detection tests with different principles in patients with past COVID-19, the sensitivity and specificity values of the most effective tests were; 86.7%/99.4% (Abbott), 86.1%/98.9% (Dia.Pro), 91.3%/95% (RedCell). Between the IgM detection tests with different principles in current COVID-19 patients, the sensitivity and specificity values were; 67.8%/99.4% (Abbott), 68.9%/98.6% (Vircell), 50%/97.5% (RedCell). Abbott IgM with a kappa coefficient of 0.67 and Vircell IgM + IgA test with a kappa coefficient of 0.65 showed the best fit in patients with current COVID-19 infection. In patients with past COVID-19, Abbott IgG with 0.86 kappa coefficient and Dia.Pro IgG test with 0.85 kappa coefficient showed the best match. Due to the low sensitivity of IgM detection antibody tests, they should not be preferred instead of real-time reverse transcriptase polymerase chain reaction in routine diagnosis. IgG detection tests may be preferred to detect the antibody response and the titers in people who have had COVID-19 for population seroprevalence and especially therapeutic immune plasma production. However, it is thought that the combined use of both ECLIA/CLIA-based and EIA/ELISA-based tests together may be more effective in routine use for SARS-CoV-2 IgG tests.

7 October 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
NGNesrin Gareayaghi
Nesrin Gareayaghi
Mehmet DemirciMehmet Demirci
Mehmet Demirci
DÖDoğukan Özbey
Doğukan Özbey
Ferhat Osman DaşdemirFerhat Osman Daşdemir
Ferhat Osman Daşdemir
HDHarika Öykü Dinç
Harika Öykü Dinç
BKBekir Kocazeybek
Bekir Kocazeybek
This study aimed to determine the anti-S (receptor binding protein) RBD IgG antibody titers formed against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the neutralizing antibody inhibition percentages (nAb IH%) in blood samples taken after two doses of inactive or mRNA-based vaccine and a booster dose. Volunteers with two doses of inactivated CoronaVac (heterologous group; n = 75) and BioNTech (BNT)162b2 mRNA vaccine (homologous group; n = 75) were included in this study. All participants preferred the BNT162b2 vaccine as a booster dose. First, peripheral blood samples were taken 3 months after the second vaccine dose. Second, peripheral blood samples were taken 1 month after the booster dose. Anti-S-RBD IgG titers were determined by CMIA (SARS-CoV-2 IgG II Quant). Neutralizing antibodies were detected by a surrogate neutralization assay (SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Germany). The median age of the volunteers was 40 (IQR 29–47) years old. After the heterologous booster dose, anti-S-RBD IgG levels and neutralizing antibodies increased approximately 50-fold and 9-fold, respectively. Anti-S-RBD IgG titers increased by 9 and 57 times, respectively, while nAb IH% increased by 1.5 and 16 times, respectively, among those with heterologous reminder doses and those with and without a prior history of coronavirus disease (COVID-19). This study showed that after the administration of a heterologous booster dose with BNT162b2 to those whose primary vaccination was with inactivated CoronaVac, the binding and neutralizing antibody levels were similar to those who received a homologous BNT162b2 booster dose. It was observed that the administration of heterologous and homologous booster doses resulted in the development of similar levels of neutralizing antibodies, independently from a prior history of COVID-19.

30 September 2021 in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
Verified
Journal Article
Open access
TSTevhide Zi̇ver Sarp
Tevhide Zi̇ver Sarp
HDHarika Öykü Dinç
Harika Öykü Dinç
DÖDoğukan Özbey
Doğukan Özbey
SASeher Çeli̇k Akkuş
Seher Çeli̇k Akkuş
BABeyza Aslan
Beyza Aslan
BKBekir Kocazeybek
Bekir Kocazeybek
Objective: Hepatitis Delta Virus is a defective virus that can cause co-infection, superinfection and chronic hepatitis delta infection with Hepatitis B Virus. In this study, it was aimed to retrospectively determine the seroprevalence of HDV infection in patients who applied to Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Microbiology Laboratory with suspected HBV and / or HDV infection between January 2014 and September 2019. Material and Method: HBsAg, anti-HBc IgM, anti HBc (total) HBeAg, anti HBe, anti HBs, anti HDV, HBV DNA and HDV RNA test results were evaluated in the blood of 1374 patients who were admitted with the suspicion of HBV and / or HDV infection between January 2014 and September 2019. Results: The age range of 1374 patients diagnosed with HBV was to 8 to 87 years and 585(%42.6) were female and 789(%57.4) were male. As a result of the analysis, anti HDV positive was detected in 7.9% of 1374 patients. In 2014, it was determined that 1.2% of the patients with positive were acute HBV, 27.3% were chronic HBV and 5.7% were inactive carriers. Between 2015-2019, it was determined that 7.2% of the patients with positive were acute HBV, 8.3% had chronic hepatitis and 9.9% had chronic infection. Although anti-HDV positive was significantly higher in females than males (p <0.05), it was found that there was no statistically significant difference between age groups. Conclusion: Although our study results are similar to the results of prevalence studies conducted in the western region in recent years, they show that the prevalence of anti HDV is in an upward trend, albeit slightly.We think that large-scale studies should be conducted in order to reveal current prevalence data Giriş ve Amaç: Hepatit Delta Virüsü, Hepatit B virüs varlığında koenfeksiyon, süperenfeksiyon ve kronik hepatit delta enfeksiyonu yapabilen defektif bir virüstür. Bu çalışmada, Ocak 2014-Eylül 2019 tarihleri arasında İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi Mikrobiyoloji Laboratuvarına HBV ve/veya HDV enfeksiyonu şüphesi ile başvuran olgularda retrospektif olarak HDV enfeksiyonu seroprevalansının belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Ocak 2014-Eylül 2019 tarihleri arasında HBV ve/veya HDV enfeksiyon şüphesi ile başvuran 1374 hasta kanında HBsAg, anti-HBc IgM, anti HBc(total) HBeAg, anti HBe, anti HBs, anti HDV, HBV DNA ve HDV RNA test sonuçları olarak değerlendirilmiştir. Bulgular: Çalışmaya alınan HBV tanılı 1374 hastanın yaşları 8-87 arasında olup, 585’inin(%42.6) kadın, 789’unun(%57.4) erkek olduğu belirlenmiştir. Yapılan analizler sonucunda 1374 hastanın %7.9’unda anti HDV pozitifliği saptanmıştır. 2014 yılında pozitif saptanan hastaların %1.2’sinin akut HBV, %27.3’ünün kronik HBV ve %5.7’sinin inaktif taşıyıcı olduğu belirlenmiştir. 2015-2019 yılları arasında pozitif saptanan hastaların ise %7.2’sinin akut HBV, %8.3’ünün kronik hepatit ve %9.9’unun kronik enfeksiyonu olduğu belirlenmiştir. Anti HDV pozitif saptanan olgular içerisinde kadın bireylerde anti-HDV pozitifliği erkeklere göre anlamlı düzeyde yüksek bulunmakla birlikte(p<0,05), yaş grupları arasında istatistiksel olarak anlamlı düzeyde fark olmadığı saptanmıştır. Sonuç: Çalışma sonuçlarımız son yıllarda batı bölgesinde yapılan prevalans çalışmalarının sonuçlarına benzer bulunmakla birlikte, anti HDV prevalansının az da olsa yükseliş eğiliminde olduğunu göstermektedir. Güncel prevalans verilerinin ortaya koyulabilmesi için geniş çaplı çalışmalar yapılması gerektiğini düşünmekteyiz.

1 October 2020 in Journal of Infection and Public Health
Verified
Journal Article
Open access
EAErsan Atahan
Ersan Atahan
SSSuat Saribas
Suat Saribas
Mehmet DemirciMehmet Demirci
Mehmet Demirci
ABAylin Babalık
Aylin Babalık
SASeher Akkus
Seher Akkus
BKBekir Kocazeybek
Bekir Kocazeybek
The antigen 85 complex (85B) is secreted in large quantities from growing mycobacteria and the presence of bacterial mRNA is an indicator of cell viability. The quantitative detection of 85B mRNA expression levels can be used to assess the success of anti-tuberculosis treatment outcomes to detect viable mycobacteria cells. Therefore, we evaluated the levels of 85B mRNA of Mycobacterium tuberculosis strains in patients with pulmonary tuberculosis. Thirty patients with primary tuberculosis were included in this study. The sputum specimens of patients were collected on days 0, 15, and 30 days and were cultured and evaluated by 85B mRNA-based RT-qPCR. Overall, 23 of the studied tuberculosis strains were susceptible to the primary anti-tuberculosis antibiotics used in this study, 7 were resistant. By the 30th day of treatment, 85B mRNA was detected in only one of the susceptible strains, but in all 7 of the resistant strains, though the relative gene expression varied between the strains. This difference between the susceptible and resistant strains at day 30 was statistically significant (p < 0.05). 85B mRNA expression levels could be used to follow up on primary tuberculosis cases. 85B mRNA seems to be a good diagnostic marker for monitoring anti-tuberculosis treatment outcomes.